Tumors
2 competing products in clinical development for Tumors.
Pipeline by Phase
Phase 12
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Cixutumumab | Eli Lilly | Phase 1 | Completed | 33 |
| ZN-c3 + Bevacizumab + Pembrolizumab | Zentalis Pharmaceuticals | Phase 1 | Withdrawn | 25 |